Jeremy Green, Redmile Group Drop Cyclacel Pharmaceuticals Like It’s Hot

Jeremy Green, Redmile Group: In a passive 13G filing with the SEC just now, the San Francisco-based Redmile Group, managed by Jeremy Green, has closed out its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC). Cyclacel is a bio-therapeutics firm focusing on antibody-based treatments. Shares are down over 5% on the day.

Disclosure: none